GeneVentiv Therapeutics
Raleigh, US · Founded 2020 · Delaware corporation
Founders & leadership
RL
Richard LimehouseNamed on SEC filing
DR
Damon RaceNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 1 round · 2022
▶$1.4MraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
▶$1.4MraisedAug 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard LimehouseDirector
- Damon RaceExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.4M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Enliven Therapeutics5 shared keywordsEnliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML). It focuses on drug candidates with differentiated profiles across efficacy, tolerability, and dosing for clinical use.
GEn1E Lifesciences5 shared keywordsGen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.
Companies competing with GeneVentiv Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- How much funding has GeneVentiv Therapeutics raised?
- GeneVentiv Therapeutics has disclosed $1.4M raised across 1 round.
- Where is GeneVentiv Therapeutics headquartered?
- GeneVentiv Therapeutics is headquartered in Raleigh, US.